IFN-alpha receptor-1 upregulation in PBMC from HCV naïve patients carrying CC genotype. Possible role of IFN-lambda

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Lalle, Eleonora ^a   Bordi, Licia ^a   Caglioti, Claudia ^a   Garbuglia, Anna Rosa ^a   Castilletti, Concetta ^a   Taibi, Chiara ^a   Cristofari, Francesca ^a   Capobianchi, Maria Rosaria ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

'INTRON'; INTERFERON; INTERFERON ALPHA RECEPTOR 1; INTERFERON LAMBDA; INTERFERON RECEPTOR; INTERLEUKIN 28B; MESSENGER RNA; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CYTOKINE RESPONSE; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOTE; HUMAN; HUMAN CELL; IFN LAMBDA GENE; IFNAR 1 GENE; IL 28B GENE; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRAL CLEARANCE; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETICS; HEPACIVIRUS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; UPREGULATION; VERY ELDERLY; VIROLOGY; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, INTERFERON ALPHA-BETA; RNA, MESSENGER; UP-REGULATION; VIRAL LOAD;

EID: 84898651998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093434     Document Type: Article

References (32)

1. World Health Organization (2010) Sixty-Third World Health Assembly. Viral Hepatitis, Report by the Secretariat A63/15
2. Strader DB, Wright T, Thomas DL, Seeff LB (2004) American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-71.
3. European Association for the Study of the Liver (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55: 245-64.
4. Hadigan C, Kottilil S (2011) Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA 306: 294-301.
5. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, et al. (2005) Plasma chemokine levels correlate with the outcome of (Pubitemid 41129575)
6. Lalle E, Calcaterra S, Horejsh D, Abbate I, D'Offizi G, et al. (2008) Ability of peripheral blood mononuclear cells to activate interferon response in vitro is predictive of virological response in HCV patients. J Biol Regul Homeost Agents 22: 153-60.
7. Giannelli G, Guadagnino G, Dentico P, Antonelli G, Antonaci S (2004) MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res 24: 659-63. (Pubitemid 39546353)
8. Gerotto M, Dal Pero F, Bortoletto G, Realdon S, Ferrari A, et al. (2004) PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C. Antivir Ther 9: 763-70. (Pubitemid 39434340)
9. Chen L, Borozan I, Feld J, Sun J, Tannis LL, et al. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437-44. (Pubitemid 40712193)
10. Donnelly RP, Kotenko SV (2010) Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30: 555-64.
11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
12. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-9.
13. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL-28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-4.
14. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, et al. (2010) An IL-28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139: 821-7, 827.
15. Riva E, Scagnolari C, Monteleone K, Selvaggi C, Picardi A, et al. (2012) Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients. J Viral Hepat 19: 650-3.
16. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, et al. (2010) Replicated association between an IL-28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138: 2307-14.
17. Lange CM, Zeuzem S (2011) IL-28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 55: 692-701.
18. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, et al. (2011) Interferon-lambda serum levels in hepatitis C. J Hepatol 54: 859-65
19. Torres C, Brahm J, Venegas M (2013) J Lambda Interferon Serum Levels in Patients with Chronic Hepatitis C Virus Infection According to Their Response to Therapy with Pegylated Interferon and Ribavirin. Interferon Cytokine Res. Sep 26.
20. Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, et al. (2012) Dysregulation of innate immunity in hepatitis C virus genotype 1 IL-28Bunfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 56: 444-54.
21. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL-28B genotype is associated with differential expression of intrahepatic interferonstimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-96.
22. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499-509.
23. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferoninduced gene expression is a stronger predictor of treatment response than IL-28B genotype in patients with hepatitis C. Gastroenterology 140: 1021-31.
24. Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, et al. (2012) Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 55: 20-9.
25. Abbate I, Romano M, Longo R, Cappiello G, Lo Iacono O, et al. (2003) Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. J Med Virol 70: 581-7. (Pubitemid 36734722)
26. Capobianchi MR, Lalle E, Martini F, Poccia F, D'Offizi G (2006) Influence of GBV-C infection on the endogenous activation of the IFN system in HIVcoinfected patients. Cell Mol Biol 52: 3-8. (Pubitemid 43925156)
27. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, et al. (2004) Interferon type I gene expression in chronic hepatitis C. Lab Invest 84: 1148-59. (Pubitemid 39128260)
28. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, et al. (2011) IL-28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 54: 1094-101.
29. François-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, et al. (2011) USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon a response. PLoS One 6: e22200.
30. Fukuda R, Ishimura N, Kushiyama Y, Moriyama N, Ishihara S, et al. (1997) Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol. 26: 455-461. (Pubitemid 27112707)
31. Mathai J, Shimoda K, Banner BF, Mori M, Bonkovsky HL, et al. (1999) IFNalpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. J Interferon Cytokine Res. 19: 1011-8. (Pubitemid 29445057)
32. Booy S, van Eijck CH, Dogan F, van Koetsveld PM, Hofland LJ (2014) Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells. J Cell Mol Med 20: 1-11.